Screener
ANI Pharmaceuticals ANIP Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating income | 40,460 | 13,892 | 79,348 | 40,086 |
| Other (expense) income, net | ||||
| Unrealized gain (loss) on investment in equity securities | 741 | 332 | 6,494 | (589) |
| Interest expense, net | (3,636) | (5,438) | (7,405) | (10,922) |
| Other (expense) income, net | (468) | 1,739 | (1,119) | 1,937 |
| Income Before Income Tax Expense | 37,097 | 10,525 | 77,318 | 30,512 |
| Income tax expense | 12,386 | 1,976 | 23,115 | 6,282 |
| Net Income | $24,711 | $8,549 | $54,203 | $24,230 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's interest expense?
- ANI Pharmaceuticals (ANIP) reported interest expense of -$3.64M in Q2 2026.
- How has ANI Pharmaceuticals's interest expense changed year-over-year?
- ANI Pharmaceuticals's interest expense increased by 33.1% year-over-year, from -$5.44M to -$3.64M.
- What is the long-term trend for ANI Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's interest expense has grown at a 13.9% compound annual growth rate (CAGR), from -$11.92M to -$20.06M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about ANI Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude